Teva Pharmaceutical Industries (NYSE:TEVA) Earns Overweight Rating from Piper Sandler

Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “overweight” rating reaffirmed by analysts at Piper Sandler in a research note issued on Wednesday,Benzinga reports. They currently have a $41.00 price objective on the stock, up from their previous price objective of $40.00. Piper Sandler’s target price points to a potential upside of 29.26% from the stock’s previous close.

Other equities research analysts have also issued reports about the company. Jefferies Financial Group raised their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. Bank of America raised their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Finally, Truist Financial lifted their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $31.72 on Wednesday. Teva Pharmaceutical Industries has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The firm has a market capitalization of $36.47 billion, a PE ratio of 26.43, a PEG ratio of 11.02 and a beta of 0.72. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The stock’s fifty day moving average is $33.03 and its 200 day moving average is $26.11.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the company earned $0.71 EPS. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Eliyahu Sharon Kalif sold 345,810 shares of the business’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $33.64, for a total value of $11,633,048.40. Following the completion of the sale, the executive vice president owned 57,478 shares in the company, valued at approximately $1,933,559.92. The trade was a 85.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the transaction, the vice president directly owned 48,384 shares in the company, valued at approximately $1,387,653.12. The trade was a 70.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 1,210,805 shares of company stock worth $38,221,390. 0.49% of the stock is currently owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors have recently modified their holdings of TEVA. Aster Capital Management DIFC Ltd acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $25,000. Allworth Financial LP lifted its holdings in shares of Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares during the last quarter. Grove Bank & Trust lifted its holdings in shares of Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after purchasing an additional 345 shares in the last quarter. Finally, Advisors Asset Management Inc. purchased a new position in Teva Pharmaceutical Industries during the 2nd quarter worth $41,000. 54.05% of the stock is currently owned by institutional investors.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Blackstone Life Sciences agreed to provide up to $400M to fund development of Teva’s duvakitug program, de‑risking late‑stage funding and sharing development risk/costs for a drug that will compete with therapies from Merck and Roche. Teva, Blackstone Life Sciences Enter $400M Funding Agreement for Duvakitug
• Positive Sentiment: Piper Sandler reaffirmed an “overweight” rating and raised its price target to $41, signaling analyst confidence in upside (about ~29% above the recent price) which can support buyer interest. Piper Sandler PT Raise
• Positive Sentiment: Recent quarterly results were strong (Q4 beat on EPS and revenue and management set FY26 guidance of $2.57–2.77 EPS), providing fundamental support for valuation and dividend coverage.
• Neutral Sentiment: Coverage pieces note that generics makers face pricing pressure, but Teva is pursuing complex generics and biosimilars as growth levers — a mixed industry outlook that tempers both bull and bear cases. 3 Generic Drug Stocks to Watch Despite Industry Headwinds
• Neutral Sentiment: Industry commentary on broader trends such as AI adoption is relevant long term but not an immediate stock mover for Teva. Pharma Industry’s AI Adoption
• Negative Sentiment: CEO Richard Francis sold 442,935 shares (~40% reduction in his holding) for roughly $14.3M — a large insider sale that often spooks investors even when preplanned. SEC Filing: Insider Sale
• Negative Sentiment: Billionaire investor Stanley Druckenmiller reduced his Teva stake in recent filings, a high‑profile trimming that can amplify selling pressure from other funds. Druckenmiller Dumped Teva
• Negative Sentiment: Media pieces pitching alternate dividend stocks highlight competitive payout stories, which can divert income-focused buyers away from Teva while it completes its business transition. Dividend Competitor Article

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.